COVID-19 Vaccines: What They Do and How Guidance Changed
COVID-19 vaccination is now part of longer-term respiratory-disease management rather than an emergency campaign. WHO continues to emphasize vaccination for people at highest risk of severe outcomes, while national schedules differ.
At a glance
Key points
- Main benefit
- Lower risk of severe disease and death
- Manufactured types
- mRNA · protein-based
- Who benefits most
- People at highest risk
- Guidance
- Risk-based · country-specific
- First WHO EUL
- 31 Dec 2020
- Evidence evolves
- Composition and schedules change
What COVID-19 vaccines are designed to do
Vaccination trains the immune system to recognize SARS-CoV-2 without requiring the person to develop COVID-19 first. The central public-health benefit is protection against severe disease and death. Protection against infection can be less durable and is affected by viral evolution, which is why vaccine composition and revaccination guidance can change.
WHO states that vaccines it lists for emergency use or prequalifies protect against severe COVID-19 and death. As of September 2026, WHO describes mRNA and protein-based vaccines as the two types currently being manufactured.
Comparison
Current vaccine platforms in WHO guidance
Technology differs, but the goal is to generate an immune response to SARS-CoV-2 antigens.
| Platform | How it works at a high level | Current context |
|---|---|---|
| mRNA | Delivers engineered RNA instructions that allow cells to make a harmless viral protein target and stimulate an immune response. | Widely used; formulations can be updated as variants evolve. |
| Protein-based | Provides harmless viral protein fragments or protein structures to trigger immunity. | An alternative platform used in current programmes. |
Timeline
From a new viral sequence to long-term vaccination
A compressed timeline showing how quickly the evidence base and programme context changed.
- 10 Jan 2020
SARS-CoV-2 genetic sequence published
The sequence enabled rapid vaccine design and research.
- 16 Mar 2020
First COVID-19 vaccine candidate entered human testing in the United States
Public discussion emphasized the unprecedented speed of vaccine development while major questions about efficacy, manufacturing and equitable access were still unresolved.
- 31 Dec 2020
WHO issued its first COVID-19 vaccine emergency-use validation
This supported wider regulatory and procurement decisions during the emergency phase.
- 2021–2023
Large-scale vaccination and booster programmes expanded
Recommendations evolved as population immunity increased and new variants emerged.
- 2026
Risk-based vaccination is the long-term model
WHO prioritizes routine vaccination and revaccination for people at highest risk of severe disease; national schedules vary.
Evidence over time
What changed from 2020 expectations
The purpose of vaccination stayed clear even as expectations about infection-blocking protection and programme design evolved.
Journalists were covering vaccine candidates before anyone knew which products would succeed, how quickly manufacturing could scale, or how equitable access would be achieved.
Multiple vaccine platforms have been deployed at enormous scale. Current guidance focuses less on emergency mass rollout and more on maintaining protection against severe disease in higher-risk groups.
Sources
This page separates current clinical or public-health guidance from historical pandemic material. Recommendations can vary by country and may change as evidence evolves.
- 1. WHO. COVID-19 vaccines — questions and answers. Source ↗
- 2. WHO. Coronavirus disease (COVID-19) fact sheet. Source ↗
- 3. WHO. First emergency-use validation for a COVID-19 vaccine. Source ↗
This article is based on trusted medical sources and is awaiting clinician review. It is not a substitute for personalized medical advice.